FDA backs QYLEKI name as Quoin (NASDAQ: QNRX) advances QRX003
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Quoin Pharmaceuticals announced that the U.S. Food and Drug Administration has conditionally approved QYLEKI™ as the proposed brand name for QRX003, its investigational lotion for treating the rare skin disorder Netherton Syndrome. Final approval of the brand name would come only with FDA marketing approval of QRX003.
QRX003 (QYLEKI 4% lotion) is in Phase 2 whole-body clinical trials, with a pivotal Phase 3 study expected to start in the second half of 2026 and a potential New Drug Application filing anticipated in 2027. The product has Orphan Drug Designation in the U.S., European Union, and Japan, and has also received Fast Track and Rare Pediatric Disease designations from the FDA, in an area where there is currently no approved treatment.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
ADS to ordinary share ratio: 35 ordinary shares per ADS
QYLEKI lotion strength: 4%
Phase 3 timing: Second half of 2026
+2 more
5 metrics
ADS to ordinary share ratio
35 ordinary shares per ADS
American Depositary Shares structure
QYLEKI lotion strength
4%
QYLEKI lotion concentration in development
Phase 3 timing
Second half of 2026
Pivotal Phase 3 study for QRX003 expected start
Potential NDA filing year
2027
Anticipated New Drug Application for QRX003
Key regulatory designations
Orphan, Fast Track, Rare Pediatric Disease
QRX003 status in major territories
Key Terms
Orphan Drug Designation, Fast Track, Rare Pediatric Disease Designations, New Drug Application (NDA), +2 more
6 terms
Orphan Drug Designation regulatory
"QRX003 holds Orphan Drug Designation in the United States, the European Union, and Japan."
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track regulatory
"The FDA has also granted QRX003 Fast Track and Rare Pediatric Disease Designations."
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.
Rare Pediatric Disease Designations regulatory
"The FDA has also granted QRX003 Fast Track and Rare Pediatric Disease Designations."
A rare pediatric disease designation is an official label granted to an experimental drug or therapy aimed at treating serious illnesses that mainly affect children and are uncommon. It matters to investors because the designation often brings benefits such as faster review, financial incentives, or market exclusivity that can lower development risk and increase the potential commercial value—think of it as a priority pass and toolkit that can shorten and protect a company’s path to pediatric treatments.
New Drug Application (NDA) regulatory
"A request for proprietary name review and final approval for QYLEKI will be included in a New Drug Application (NDA) for QRX003."
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
Phase 3 study medical
"Quoin's pivotal Phase 3 study is expected to initiate in the second half of 2026."
A phase 3 study is the large-scale clinical trial that tests whether a new drug or medical treatment actually works and is safe in a broad group of patients, typically after earlier smaller tests. Investors watch these studies like a final dress rehearsal because their successful completion is often required for regulatory approval and market access; positive or negative results can sharply change a company’s future sales prospects and stock value.
Pediatric Compassionate Use Program medical
"Having just released a positive update from our ongoing Pediatric Compassionate Use Program and with our pivotal Phase 3 study expected to commence later this year..."
FAQ
What did Quoin Pharmaceuticals (QNRX) announce about QYLEKI and QRX003?
Quoin reported FDA conditional approval of QYLEKI™ as the proposed brand name for QRX003. QRX003 is an investigational lotion for Netherton Syndrome, a rare inherited skin disorder with no currently approved treatments.
What is QRX003 (QYLEKI) being developed to treat at Quoin Pharmaceuticals (QNRX)?
QRX003, proposed brand name QYLEKI™, is being developed to treat Netherton Syndrome. This is a rare inherited skin disorder with severe barrier dysfunction and no FDA-approved therapies, leaving patients with limited supportive and off-label treatment options.
What regulatory designations has Quoin’s QRX003 (QYLEKI) received?
QRX003 has Orphan Drug Designation in the United States, European Union, and Japan. The FDA has also granted Fast Track and Rare Pediatric Disease designations, reflecting regulatory recognition across Quoin’s three core commercial territories.
What is the clinical development timeline for Quoin’s QRX003 (QYLEKI)?
QYLEKI lotion (4%) is currently in Phase 2 whole-body clinical trials for Netherton Syndrome. Quoin expects to start a pivotal Phase 3 study in the second half of 2026, with a potential New Drug Application filing anticipated in 2027.
When will QYLEKI’s brand name receive final FDA approval for Quoin Pharmaceuticals (QNRX)?
Final approval of the QYLEKI brand name will occur only upon FDA marketing approval of QRX003. A request for proprietary name review and final approval is planned to be included in the future New Drug Application for this investigational product.
Does Netherton Syndrome currently have any approved treatments?
There are currently no FDA-approved therapies for Netherton Syndrome. Patients typically rely on supportive care and off-label treatments, so if approved, QRX003 (QYLEKI) could become the first approved therapy for this rare skin disorder.